Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection

Prior treatment

• Receiving any form of C1-INH therapy either acute or prophylactic treatment
• Currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study or have discontinued with 30 days of study entry from any other clinical study involving an investigational product

Other illness

• History or suspicion of allergy to rabbits
• Neurological conditions related to injury
• Neuropathy related to diabetes

Other

• Participants who are pregnant or lactating
• Largely incapacitated or bed ridden
• Patients who, in the investigator's opinion, might not be suitable for the trial for safety reasons

• Age 18 and older, male or female
• Previous confirmed diagnosis of SARS-CoV-2
• Experiencing SARS-CoV-2 post-viral fatigue syndrome 4 weeks after recovery for SARS-CoV-2
• Experiencing neurological symptoms including fatigue
• Willing to comply with all aspects of the protocol, including blood draws
• Patient is able to understand and fully participate in the activities of the study and the consent in accordance with guidelines
• Female patients of childbearing potential who are sexually active must be willing to use an acceptable form of contraception. Acceptable forms of contraception are defined as those with a failure rate of \< 1% when properly applied and include: a combination pill, some intra-uterine devices, and a sterilized partner in a stable relationship. Female patients must not be pregnant, planning to become pregnant, or be actively breastfeeding through the entire period.